Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.59 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7854088 | 0.86 | NOTUM (0.56) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL1821339 | 0.86 | NOTUM (0.56) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL29709501 | 0.85 | MBTD1 (0.53) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL931643 | 0.84 | MBTD1 (0.57) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL10316005 | 0.83 | MBTD1 (0.61) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL20760190 | 0.82 | GRIN2B (0.65) | MBTD1L3MBTL3L3MBTL1GRIN2BSLC18A3 | |
| Hydrochloric Acid SCHEMBL17927700 | 0.82 | MBTD1 (0.55) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| Hydrochloric Acid SCHEMBL17748967 | 0.82 | MBTD1 (0.55) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL9071141 | 0.79 | MBTD1 (0.57) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 | |
| SCHEMBL3537362 | 0.79 | MBTD1 (0.57) | MBTD1L3MBTL3L3MBTL1LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598798-A | Preparation method for directly synthesizing arylamine compound based on aromatic hydrocarbon and fatty amine | 沈阳药科大学 | 2024-09-06 | — | — | CN | disclosed |
| US-7514431-B2 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1558576-A4 | PIPERIDINYL CYCLOPENTYL ARYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20060173013-A1 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-08-03 | — | — | US | disclosed |
| EP-1558576-A2 | PIPERIDINYL CYCLOPENTYL ARYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041163-A2 | PIPERIDINYL CYCLOPENTYL ARYL BENZYLAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6531471-B2 | Antagonists for human alpha 1a receptors; lowering intraocular pressure; inhibiting cholesterol synthesis; relaxing lower urinary tract tissue; treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-03-11 | — | — | US | disclosed |
| US-6410554-B1 | ADRENERGIC ANTAGONIST | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARAMCEUTICAL CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6362182-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; BENIGN PROSTATIC HYPERTROPIC | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140876-A1 | MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6218390-B1 | FOR LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, RELAXING LOWER URINARY TRACT TISSUE, THERAPY OF BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, CARDIAC ARRHYTHMIA, SYMPATHETIC MEDIATED PAIN, MIGRAINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000035891-A1 | MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999048530-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173013-A1 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | CCR2, CCR1, CCRL2 | MBTD1 2208/4885L3MBTL3 4553/4885L3MBTL1 4079/4885 |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | MBTD1 168/4885L3MBTL3 2901/4885L3MBTL1 1732/4885 |
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | MBTD1 168/4885L3MBTL3 2901/4885L3MBTL1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.